
ISSN 2220-5187 | Pharma Rev
An interdisciplinary, peer-reviewed, open access professional journal of the pharmaceutical, medical and life sciences, established in 2010
ISSN 2220-5187 · Journal DOI 10.52182/22205187 · Abbreviation: Pharm Rev · Published annually in English
Pharmaceutical Review shares credible scientific and professional knowledge across the pharmaceutical, medical and life sciences. It publishes peer-reviewed research and reviews. Alongside them it publishes clearly labelled professional content, such as expert interviews, analyses of scientific developments, and reports on conferences, workshops and exhibitions.
The journal connects researchers, healthcare professionals, academic institutions, policymakers and industry. It works under structured editorial governance, evidence-based review standards and principles of responsible scientific communication. All content is free to read, download and reuse from the day of publication.
Mission. To share reliable, high-quality scientific and professional knowledge in the pharmaceutical, biological, medical and healthcare sciences, supporting research, healthcare development and global knowledge exchange.
Vision. To become a globally recognised interdisciplinary platform for scientific communication that promotes innovation, evidence-based practice, professional collaboration and responsible scholarly publishing.
Key title: Pharmaceutical Review
Abbreviation: Pharm Rev
ISSN: 2220-5187
Crossref DOI: https://doi.org/10.52182/22205187
Established: 2010
Frequency: Annual (articles published online on acceptance)
Format: Online
Language: English; selected professional features in Urdu
Peer review: Double-blind, at least two reviewers (research and review articles)
Licence: CC BY 4.0
Copyright: Journal, publisher and authors (jointly held)
Publication charges: None. No submission fee, article processing charge or open access charge
Submission: Online
Publisher: Consortium Publisher – ICDTD Inc., Canada
Contact: office@consortiumpublisher.ca · +1 (647) 526-0885
The journal publishes scientific and professional content that improves the discovery, development, safe use and regulation of medicines, and the wider practice of health care. It values research that links a clear question to sound methods and appropriate analysis, with conclusions that stay within the evidence.
The journal aims to:
Publish rigorous, peer-reviewed research and reviews across the pharmaceutical, medical and life sciences.
Connect researchers with healthcare professionals, policymakers and industry through clearly labelled professional content.
Support collaboration among academic institutions, professional organisations and industry.
Make all content openly available, so that researchers, practitioners, educators and students everywhere can use it without cost.
Within scope: laboratory, clinical, field and population studies with appropriate methods and analysis, and systematic and narrative reviews with full references. Also within scope: evidence-based professional analyses, expert interviews, and reports on scientific meetings and innovations.
Outside scope: unsupported therapeutic or commercial claims, promotional material presented as research, and personal allegations not supported by documented evidence. Studies whose conclusions rest on data that are not made available for review are also outside scope.
The subject areas are grouped into eight themes. They run from medicines and the people who use them, through the wider health professions and public health, to the agricultural, biological and technological sciences that support them.
1. Pharmaceutical sciences and pharmacy. Pharmacy, pharmaceutical sciences, pharmacology and toxicology. This theme asks how medicines are developed, tested, regulated and used safely.
2. Medicine, dentistry and clinical research. Medicine and clinical research, and dentistry and oral health. This theme asks how diseases are diagnosed, treated and prevented in patients.
3. Nursing and allied health sciences. Nursing and the allied health professions. This theme asks how health professionals can deliver safe, effective care.
4. Public health and epidemiology. Public health, epidemiology and health policy. This theme asks how the health of whole populations can be measured, protected and improved.
5. Veterinary, agricultural and livestock sciences. Veterinary sciences, agricultural sciences and livestock sciences. This theme asks how animal and crop health support human health and the food supply.
6. Food science and nutrition. Food science and nutrition. This theme asks how food composition, safety and diet affect health.
7. Biotechnology, microbiology and molecular biology. Biological and life sciences, biotechnology, medical microbiology and molecular biology. This theme asks how living systems work at the molecular level, and how that knowledge is applied in health and industry.
8. Biomedical and healthcare technologies. Biomedical technologies, healthcare innovations and digital health. This theme asks how new technologies can improve diagnosis, treatment and the delivery of care.
Work from universities, hospitals, industry, regulators and professional organisations is welcome in every theme.
Peer-reviewed articles
Original research article: reports new laboratory, clinical, field or population findings that answer a defined research question.
Review article: critically synthesises published evidence on a topic and identifies open questions. Systematic reviews should follow PRISMA.
Mini-review: a concise, evidence-based review of a focused topic, with full references.
Short communication: reports a focused, significant finding that does not need a full article.
Professional content (reviewed by the editors, not peer reviewed)
Professional analysis or update: an evidence-based account of developments in practice, regulation or industry.
Expert interview: an edited interview with a researcher, practitioner or policymaker.
Scientific developments and innovations: reports on new technologies, products or research initiatives.
Conference and event report: coverage of academic conferences, workshops, seminars and exhibitions.
Commentary or opinion: a signed viewpoint on a current issue, clearly labelled as opinion.
Every item is labelled with its content type. Only peer-reviewed articles appear in the research section and carry the label “Peer reviewed”.
Pharmaceutical Review is a fully open access journal that follows the Directory of Open Access Journals (DOAJ) definition of open access. All content is free to read immediately on publication, with no subscription, registration or embargo.
Licence. Articles are published under the Creative Commons Attribution 4.0 International licence (CC BY 4.0). Anyone may read, download, copy, distribute, print, search or link to the full text, crawl it for indexing, pass it as data to software, or use it for any other lawful purpose, as long as the original authors and source are properly cited. The licence statement appears on every article page and in the article PDF.
Copyright. The journal, the publisher (Consortium Publisher – ICDTD Inc.) and the authors hold copyright of each article jointly. The journal has the right to publish the article first. Because articles are published under CC BY 4.0, anyone may reuse them with proper citation. Authors may deposit any version of their article, including the published version, in institutional or subject repositories at any time.
Third-party material. Authors must get permission for any figures, photographs, tables or text reused from other sources and label them with their original licence.
Pharmaceutical Review charges no fees. There is no charge to read any content, and authors pay no submission fee, article processing charge or open access charge.
Every research and review manuscript first receives an editorial assessment of its scope, originality and research integrity, including a similarity check. Manuscripts that pass are assessed by at least two independent expert reviewers under a double-blind model. Reviewers do not know the authors’ identities, and authors do not know the reviewers’. Decisions rest on scientific validity, methodological soundness, ethical compliance and contribution to the field.
Professional content is reviewed by the editors for accuracy, fairness and relevance, but it is not peer reviewed and is never labelled as such.
Editorial independence. An editor with a conflict of interest in a manuscript does not handle it. Such manuscripts are assigned to another editor and reviewed under the same process. Sponsors, advertisers and the publisher take no part in editorial decisions.
The journal follows the Core Practices of the Committee on Publication Ethics (COPE) and the ICMJE Recommendations for the conduct, reporting and editing of scholarly work.
Originality and plagiarism. Every submission is screened for text similarity before review. Plagiarism, duplicate publication and redundant publication lead to rejection or, after publication, retraction.
Human research. Studies involving people, patient data or human samples must have approval from a named ethics committee and record informed consent. They must follow the Declaration of Helsinki and Canada’s TCPS 2.
Clinical trials and reporting standards. Clinical trials must be registered in a public registry before enrolment begins and reported according to CONSORT. Observational studies should follow STROBE.
Animal research. Studies involving animals must have institutional approval, follow the Canadian Council on Animal Care (CCAC) guidelines or an equivalent, and be reported according to ARRIVE.
Authorship. All authors must meet the ICMJE authorship criteria. Authors are encouraged to describe each contribution using the CRediT taxonomy and to provide an ORCID iD.
Conflicts of interest and funding. Authors must disclose all funding and any financial or professional interest that could affect the work. This includes links to pharmaceutical, medical device, food or agricultural companies.
Sponsored and promotional content. Sponsored content is clearly labelled as sponsored. It is never presented as research or as peer reviewed, and sponsors have no influence on editorial content.
Statements about identifiable people. Commentary that makes claims about named people or institutions is published only when it is supported by documented, verifiable evidence and has been reviewed by the editors. Those named are offered a chance to reply. Such content is labelled as opinion and never presented as peer-reviewed research.
Data availability. Each research article includes a data availability statement. Where data cannot be shared, the statement explains why and how they can be accessed.
Use of artificial intelligence. AI tools cannot be listed as authors. Any use of AI in research or writing must be disclosed, and authors remain responsible for all content.
Corrections and retractions. Errors are corrected through linked correction notices. Retractions follow COPE guidelines and remain openly accessible, with the reason stated.
Complaints and appeals. Authors, readers and anyone named in published content may raise a complaint or appeal in writing with the editorial office. Complaints are handled according to the COPE flowcharts.
Every peer-reviewed article receives a permanent Digital Object Identifier (DOI) registered with Crossref under the journal DOI 10.52182/22205187. The DOI means an article can always be found and cited, even if web addresses change.
Machine-readable metadata. Article metadata is deposited with Crossref, so indexing services and software can harvest it. The metadata includes titles, authors, affiliations, abstracts, references, licence and funding.
English is the journal’s primary language. Selected professional features may be published in Urdu or other languages for regional readers. Each one carries an English title and abstract.
Manuscripts are submitted and processed online, and authors can follow each stage of review in their account. The journal is published by Consortium Publisher – ICDTD Inc., Canada. Its website is hosted on Bravo Journal Systems (BJS) of Bravo Skills College, Port of Spain, Trinidad and Tobago.
Before submitting, please read the Author Guidelines and prepare a cover letter. Include statements on ethics approval, consent, funding, conflicts of interest and data availability.
[Submit a manuscript] · [Author Guidelines] · [Editorial Board] · [Contact the editorial office]